Remitting neuropsychiatric symptoms in COVID‐19 patients: Viral cause or drug effect?
| Autor: | Iriana Paola Mozo Herrera, Natasha A. Camejo-Ávila, Carlos Ferro, Joselyn Páez Paz, David M. Flora-Noda, Carlos G. Morantes Rodríguez, Emilia Mia Sordillo, Matthew M. Hernandez, Iván Bolívar Collado Espinal, Luis A. Perez-Garcia, Lourdes A. Delgado-Noguera, Alberto Paniz-Mondolfi, María Eugenia Landaeta, David A. Forero-Peña, Viledy L. Velásquez, Andrea L. Maricuto |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Exacerbation SARS-CoV-2 business.industry Mental Disorders viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 virus diseases Chloroquine Mental disease Virology COVID-19 Drug Treatment Infectious Diseases Internal medicine medicine Humans business Dexamethasone Drug effect medicine.drug |
| Zdroj: | Journal of Medical Virology. 94:1154-1161 |
| ISSN: | 1096-9071 0146-6615 |
| Popis: | Numerous reports of neuropsychiatric symptoms highlighted the pathologic potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its relationship the onset and/or exacerbation of mental disease. However, coronavirus disease 2019 (COVID-19) treatments, themselves, must be considered as potential catalysts for new-onset neuropsychiatric symptoms in COVID-19 patients. To date, immediate and long-term neuropsychiatric complications following SARS-CoV-2 infection are currently unknown. Here we report on five patients with SARS-CoV-2 infection with possible associated neuropsychiatric involvement, following them clinically until resolution of their symptoms. We will also discuss the contributory roles of chloroquine and dexamethasone in these neuropsychiatric presentations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text